This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=103 http://www.lsis.com/goto/r103/rss 2012-02-05T11:11:06+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 SUMMARY AT A GLANCE: The expression of cholesterol 25-hydroxylase was up-regulated in the lungs of COPD patients. There was excessive production of 25-hydroxycholesterol in the airways of COPD patients and 25-hydroxycholesterol concentrations in the airways were associated with reduced lung function, elevated neutrophil counts and high IL-8 levels in sputum. ABSTRACT: Background and objective:? 25-Hydroxycholesterol (25-HC) is produced from cholesterol by the enzyme, cholesterol (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 To establish low density lipoprotein receptor (LDLR) mutant rats as a hypercholesterolemia and atherosclerosis model, we screened the rat LDLR gene for mutations using an N-ethyl-N-nitrosourea mutagenesis archive of rat gene data, and identified five mutations in its introns and one missense mutation (478T A) in exon 4. The C160S mutation was located in the ligand binding domain of LDLR and was revealed to be equivalent to mutations (C160Y/G) identified in human familial hypercholesterolemia (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8105626 |-| Title: Granules containing acid-unstable chemical in large amount |-| Inventors: Shimizu; Toshihiro (Itami, JP), Nakano; Yoshinori (Takarazuka, JP) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 The histologic characteristics of a salivary mucocele in a beagle used in a toxicity study are described in this report. A pale yellowish cyst under the mandibular skin containing frothy mucus was observed at necropsy. Microscopically, numerous villous projections arose from the internal surface of the cyst and were lined by stratified epithelial-like macrophages, which were immunopositive for macrophage scavenger receptor A. A ruptured sublingual interlobar duct connected to the lumen was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 BACKGROUND: The only data that currently exist on ramelteon (Rozerem; Takeda Pharmaceuticals North America, Inc., Deerfield, IL) ingestions is from clinical trials. To fill this gap, data on ramelteon ingestions reported to Texas poison centers during 2005-2009 were collected and analyzed. OBJECTIVES: The objective of this study was to describe how reported ramelteon ingestions were handled by Texas poison center staff and when known, the patient's final medical outcome. In cases where the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass., Jan 23, 2012 (BUSINESS WIRE) - - Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(R)(bortezomib), which updates the label to include the subcutaneous method of administration (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company today announced it has been named among the 100 Best Companies to Work For in the United States by FORTUNE. This is the second consecutive year that Millennium, a wholly owned subsidiary of Japan s largest pharmaceutical company Takeda Pharmaceutical Company Limited, has been included in the annual ranking. After breaking into the Top 100 list at number 56 last year Millennium has moved up to number 35. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Surgical or pharmacologic methods to control gonadal androgen biosynthesis are effective approaches in the treatment of a variety of non-neoplastic and neoplastic diseases. For example, androgen ablation and its consequent reduction in circulating levels of testosterone is an effective therapy for advanced prostate cancers. Unfortunately, the therapeutic effectiveness of this approach is often temporary because of disease progression to the 'castration resistant' (CRPC) state, a situation for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth OSAKA, Japan, January 18, 2012 Takeda Pharmaceutical Company Limited ( œTakeda , TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8093236 |-| Title: Weekly administration of dipeptidyl peptidase inhibitors |-| Inventors: Ogawa; Atsushi (Osaka, JP) |-| Assignee: Takeda Pharmaceuticals Company Limited (Osaka, JP) |-| Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin- -1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8092830 |-| Title: Lactic acid polymer and process for producing the same |-| Inventors: Yamamoto; Kohei (Kawagoe, JP), Tani; Tsutomu (Kawagoe, JP), Aoki; Takashi (Kawagoe, JP), Hata; Yoshio (Hokkaido, JP) |-| Assignee: Wako Pure Chemical Industries, Ltd. (Osaka, JP) Takeda Pharmaceutical Company Limited (Osaka, JP) |-| A process for producing a lactic acid polymer of 15,000 to 50,000 in weight-average molecular weight, the content of polymeric materials having not more (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Over the last two decades, identification of polymorphisms that influence human diseases is beginning to impact on the provision of medical care. The promise of genetics lies in its ability to provide insight into an individual's susceptibility to disease, the likely nature of the disease and the most appropriate therapy. For much of its history, pharmacogenomics (PGx) has been limited to relatively simple phenotypes such as plasma drug levels. Progress in genetic technologies has broadened (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) ? agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPAR? ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8088821 |-| Title: Fused cyclic compounds |-| Inventors: Yasuma; Tsuneo (Osaka, JP), Negoro; Nobuyuki (Osaka, JP), Itou; Masahiro (Osaka, JP) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| The present invention provides a compound represented by the formula (I): #STR00001# wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8088726 |-| Title: Process for producing sustained-release composition |-| Inventors: Yamamoto; Kazumichi (Kyoto, JP), Saito; Kazuhiro (Hyogo, JP), Hoshino; Tetsuo (Osaka, JP) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| A process for producing a sustained-release composition which comprises mixing an aqueous solution containing a physiologically active substance and an acid or base in a molar amount of 1.5 or more times that of the physiologically (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 The pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, M-III of resatorvid, in rats and dogs were investigated using radio-labeled M-III ([(14)C]M-III). The elimination half-life of (14)C in the plasma of rats was about 1/30 of that of dogs after iv dosing of [(14)C]M-III at 0.5 mg/kg to rats and dogs. The in vitro and in vivo plasma protein binding ratios of M-III were relatively high and the same in both the species. The intrinsic clearance (CL(int) of M-III in the rats was (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8084058 |-| Title: Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |-| Inventors: Lodin; Unchalee (North Miami Beach, FL), Cardinal; Jack (Tamarac, FL), Nangia; Avinash (Lincoln, RI) |-| Assignee: Watson Pharmaceuticals, Inc. (Corona, CA) Takeda Pharmaceutical, Co. Ltd. (Osaka, JP) |-| A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 The synthesis and biological evaluation of a series of novel 3-phenylpiperidine-4-carboxamide derivatives are described. These compounds are generated by hybridization of the substructures from two types of tachykinin NK(1) receptor antagonists. Compound 42 showed high metabolic stability and excellent efficacy in the guinea-pig GR-73637-induced locomotive activity assay at 1 and 24h after oral administration. It also exhibited good pharmacokinetic profiles in four animal species, and a low (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis. Human PLK1 has been shown to be overexpressed in various human cancers, and elevated levels of PLK1 have been associated with poor prognosis, making it an attractive target for anticancer therapy. TAK-960 is a novel, investigational, orally bioavailable, potent, and selective PLK1 inhibitor that has shown activity in several tumor cell lines including those that express multidrug resistant (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 It has been reported that in vivo biliary clearance can be predicted using sandwich-cultured rat and human hepatocytes. The predicted apparent biliary clearance (CL(bile,app) from sandwich-cultured rat hepatocytes (SCRH) based on medium concentrations correlates to in vivo CL(bile,app) based on plasma concentrations of angiotensin II receptor blockers (ARBs), HMG-CoA reductase inhibitors (statins), ?-lactam antibiotics, and topotecan. However, the predicted biliary clearance from SCRH was (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 BETHESDA, Md.-(BUSINESS WIRE)-Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced that the hearing on the Company s claims in the demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceuticals Company Limited, or Takeda, dated October 29, 2004, have concluded within the expected timeframe and we look forward to the arbitrators decision in the first quarter of 2012. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 OSAKA, Japan & LA JOLLA, Calif., Dec 20, 2011 (BUSINESS WIRE) - Takeda Pharmaceutical Company Limited and Intellikine, Inc. ("Intellikine") today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL). Also presented were biomarker data from a phase 3 study comparing VELCADE (bortezomib) and rituximab (VcR) to rituximab (R) alone in patients (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 OSAKA, Japan & PALO ALTO, Calif.-(BUSINESS WIRE)-Takeda Pharmaceutical Company Limited (TSE:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda has decided not to commercialize peginesatide in Japan. Peginesatide is an investigational therapy for use in the treatment of patients with anemia due to chronic kidney disease (CKD). Takeda and Affymax will explore other options for the commercialization rights for this product in the Japanese market, including potentially licensing (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 SAN DIEGO, Calif.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from the final five-year follow-up analysis of the international, multicenter, Phase III VISTA1 trial. The analysis assessed overall survival (OS) after treatment with VELCADE (bortezomib) in combination with melphalan and prednisone (VcMP) versus melphalan and prednisone (MP) alone, in patients with previously untreated (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome inhibitor in clinical trials. The studies evaluated once or twice weekly oral dosing of MLN9708, alone or in combination, in patients with relapsed and/or refractory or previously untreated multiple (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 SAN DIEGO-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today reported updated data from a pivotal trial of single-agent ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011 in San Diego, CA. ADCETRIS is an antibody-drug (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 SILVER SPRING, Md. & OSAKA, Japan-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD). œWe re encouraged by the panel s positive view of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 Takeda Pharmaceutical Company has announced its plan to establish a vaccine business division effective 1January 2012. The Company has also appointed Rajeev Venkayya as its leader of the Division effective 15 January 2012. Dr Venkayya currently serves as Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation. Takeda chief medical and scientific officer Tadataka Yamada said that while the global vaccine market continues to expand as emerging countries (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8071766 |-| Title: HSP90 inhibitors |-| Inventors: Chen; Young K. (San Diego, CA), Co; Erick (San Diego, CA), Guntupalli; Prasuna (San Diego, CA), Lawson; John D. (Carlsbad, CA), Notz; Wolfgang Reinhard Ludwig (San Diego, CA), Stafford; Jeffrey A. (San Diego, CA), Ton-Nu; Huong-Thu (San Diego, CA) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| The invention relates to HSP90 inhibiting compounds consisting of the formula: #STR00001# wherein the (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8071130 |-| Title: Solid preparation |-| Inventors: Kiyoshima; Kenichiro (Osaka, JP), Nakamura; Kenji (Osaka, JP), Kawano; Tetsuya (Osaka, JP), Misaki; Masafumi (Osaka, JP) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-?, -?, and -?. The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys respectively and sipoglitazar is hardly subject to first pass metabolism in either species. Following oral administration of [(14)C]sipoglitazar to rats, sipoglitazar and its metabolites were distributed to the rat tissues with relatively high concentrations in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Herein, we aimed to evaluate the recently proposed risk assessment strategies of a cytochrome P450 (CYP) mediated drug-drug interaction (DDI) according to the European Medicines Evaluation Agency (EMEA) draft guideline, and discuss the differences between this guideline and the Food and Drug Administration (FDA) draft guidance. A retrospective study on reported 35 clinical DDI cases revealed that the EMEA assessment successfully predicts moderate-to-strong DDIs, i.e. drugs that cause (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 The pathophysiology of brain damage after ischemic stroke involves a number of mechanisms leading to neuronal damage such as the excessive release of an excitatory amino acid glutamate and inflammatory reactions. Cannabinoid (CB) receptor agonists are expected to alleviate ischemic brain damage by modulating neurotransmission and neuroinflammatory responses via CB(1) and CB(2), respectively. TAK-937 is a selective and highly potent CB(1)/CB(2) receptor agonist. In this study, the effect of (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=103 United States Patent: 8067453 |-| Title: Neurotrophin production/secretion promoting agent |-| Inventors: Momose; Yu (Hyogo, JP), Murase; Katsuhiro (Dallas, TX) |-| Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP) |-| A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula: #STR00001# wherein R.sup.1 represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 GPR40/FFA1 is a G protein-coupled receptor involved in free fatty acids-induced insulin secretion. To analyze the effect of our novel GPR40/FFA1-selective agonist, TAK-875, on insulin and glucagon secretion, we performed hormone secretion assays and measured intracellular Ca2+ ([Ca2+]i) using both human and rat islets. Insulin and glucagon secretion was measured in static and dynamic conditions using groups of isolated rat and human pancreatic islets. [Ca2+]i was recorded using confocal (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Highly sensitive and accurate liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods have been developed and validated for measuring digoxin (DGX), a typical P-glycoprotein probe, in human plasma, rat plasma, and rat brain. We extracted DGX and deuterium-labeled DGX (as internal standard) from sample fluids under basic conditions using acetonitrile and sodium chloride-saturated 0.1mol/L sodium hydroxide. The upper organic layer was diluted with distilled water, and the resulting (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=103 Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed. The new Prescription Drug User Fee Act (PDUFA) action date has been set for April 25, 2012. The FDA (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 DEERFIELD, Ill., and OSAKA, Japan, Nov. 18, 2011 /PRNewswire via COMTEX/ - Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed. The new Prescription (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 PHILADELPHIA-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced results from additional analyses of the EMERALD Phase 3 studies that evaluated the investigational agent peginesatide in dialysis patients with anemia due to chronic kidney disease (CKD). The findings, presented at the American Society of Nephrology s (ASN) Kidney Week, provide further detail on the frequency of adverse events of peginesatide and epoetin alfa (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e09348/dpp_iv_inhibitors) has announced the addition of the "DPP IV Inhibitors - Global Strategic Business Report" report to their offering. DPP IV Inhibitors - Global Strategic Business Report This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs - Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/738551/nonsmall_cell_lun) has announced the addition of GlobalData's new report "Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 This report is an essential source of information and analysis on the global Non - Small Cell Lung Cancer (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 PALO ALTO, Calif.-(BUSINESS WIRE)-Affymax, Inc. (Nasdaq:AFFY) today announced that it has reached a global settlement agreement with Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) and certain of its affiliated companies to end the arbitration and litigation related to certain intellectual property emerging from a 1992-1995 research collaboration. This settlement will allow us to more fully focus our time and resources on the regulatory review process and launch preparations for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced that ADCETRIS ¢ (brentuximab vedotin) will be featured in multiple presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011, in San Diego, Calif. The presentations will include data from additional analyses (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company s portfolio, have been accepted for oral presentation at this year s American Society of Hematology (ASH) annual meeting to be held December 10-13, 2011 in San Diego, California. These abstracts include oral presentations for VELCADE (bortezomib) for Injection and five of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced that ADCETRIS ¢ (brentuximab vedotin) will be featured in multiple presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011, in San Diego, Calif. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=103 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company s portfolio, have been accepted for oral presentation at this year s American Society of Hematology (ASH) annual meeting to be held December 10-13, 2011 in San Diego, California. These abstracts include oral presentations for VELCADE (bortezomib) for Injection and five of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=103 Aim: Free fatty acids act as signalling molecules for modulating insulin secretion, and their insulinotropic effects are glucose-dependent and mediated through G protein-coupled receptor 40 (GPR40). This mechanism is a potential target for new treatments for managing diabetes. In this study we present the first clinical data for TAK-875, a novel highly selective, orally bioavailable GPR40 agonist, in Japanese patients with type 2 diabetes insufficiently controlled by diet or exercise therapy. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=103 BETHESDA, Md.-(BUSINESS WIRE)-Sucampo Pharmaceuticals, Inc. ( œSucampo ), (NASDAQ: SCMP) (SPI), an international pharmaceutical company, today reported its consolidated financial results for the quarter and year-to-date ended September 30, 2011. Sucampo reported a net loss of $4.1 million, or $0.10 per diluted share, for the third quarter compared to a net income of $1.9 million, or $0.05 per diluted share, for the same period in 2010. Sucampo reported a net loss of $20.0 million, or (…)